The story of Viagra and its parent , copyright, presents a tangled picture for potential investors. While the revolutionary drug initially produced enormous earnings, its protection has expired , leading to competing alternatives flooding the landscape . This reduction in cost presents a real obstacle for copyright and any fund considering a heavy